HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Erminia Massarelli, MD, PhD

Articles

Dr. Massarelli on First-Line ALK+ NSCLC Treatment

January 30, 2018

Erminia Massarelli, MD, PhD, MS, associate clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses the adoption of alectinib (Alecensa) as the first-line therapy in the treatment of patients with ALK-positive non–small cell lung cancer (NSCLC).